T

he Trump administration is considering rolling back an Obama-era policy that supporters say successfully lowered some prescription drug prices, but that opponents say discourages innovation.

Since taking effect last year, the policy has affected how Medicare pays for so-called biosimilars, which are highly similar versions of biologic drugs like Humira and Rituxan that are manufactured in living cells or microorganisms. In essence, the policy attempted to use certain Medicare payments to encourage more price competition among such drugs.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy